nach oben

Diabetologia

Erschienen in:

01.02.2007 | Article

Meta-analysis of the effects of n-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes

verfasst von: J. Hartweg, A. J. Farmer, R. R. Holman, H. A. W. Neil

Erschienen in: Diabetologia | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

Aim/hypothesis

To determine whether marine-derived n-3 polyunsaturated fatty acids (n-3 PUFA) (also known as omega-3 fatty acids) have beneficial effects on haematological and thrombogenic risk markers in addition to dyslipidaemia, in patients with type 2 diabetes.

Methods

A systematic review and meta-analysis of randomised controlled trials comparing dietary or non-dietary intake of n-3 PUFA with placebo in type 2 diabetes was conducted by systematically searching databases from 1966 to February 2006. Changes in C-reactive protein, IL-6, TNF-α, platelet function, fibrinogen, factor VII, von Willebrand factor, endothelial function, heart rate and blood pressure were recorded. Inclusion of studies, data extraction and quality were assessed independently in duplicate.

Results

Twelve trials involving 847 subjects with a mean treatment duration of 8.5 weeks included sufficient data to permit pooling. Compared with placebo, n-3 PUFA supplementation had a significant effect on two outcomes: reducing the level of diastolic blood pressure (five trials, 248 subjects) by a mean of 1.8 mm Hg (95% CI 0.0–3.6, p = 0.05) and increasing factor VII (two trials, 116 subjects) by 24.9% (95% CI 7.2–42.6, p = 0.006). There were no significant effects on systolic blood pressure, fibrinogen or heart rate.

Conclusions/interpretation

These results suggest that, in addition to the recognised effects on dyslipidaemia, n-3 PUFA decreases diastolic blood pressure, and appears to increase factor VII. Larger and more rigorously conducted clinical trials are required to establish conclusively the role of n-3 PUFA in cardiovascular risk markers and clinical outcomes in type 2 diabetes.

Bonora E, Kiechl S, Willeit J et al (2004) Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes 53:1782–1789PubMedCrossRef

Din JN, Newby DE, Flapan AD (2004) Omega 3 fatty acids and cardiovascular disease—fishing for a natural treatment. Br Med J 328:30–35CrossRef

Erkkila AT, Lichtenstein AH, Mozaffarian D, Herrington DM (2004) Fish intake is associated with a reduced progression of coronary artery atherosclerosis in postmenopausal women with coronary artery disease. Am J Clin Nutr 80:626–632PubMed

Hu FB, Cho E, Rexrode KM, Albert CM, Manson JE (2003) Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women. Circulation 107:1852–1857PubMedCrossRef

Hooper L, Thompson RL, Harrison RA et al (2006) Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. Br Med J 332:752–760CrossRef

Dickersin K, Scherer R, Lefebvre C (1994) Identifying relevant studies for systematic reviews. Br Med J 309:1286–1291

Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12PubMedCrossRef

Tramer MR, Reynolds DJ, Moore RA, McQuay HJ (1997) Impact of covert duplicate publication on meta-analysis: a case study. Br Med J 315:635–640

Rice JA (1995) Mathematical statistics and data analysis. Duxbury, California

10.

Alekseeva RI, Sharafetdinov K, Plotnikova OA, Meshcheriakova VA, Mal’tsev GI, Kulakova SN (2000) Effects of diet therapy including eiconol on clinical and metabolic parameters in patients with type 2 diabetes mellitus. Vopr Pitan 69:36–39PubMed

11.

Axelrod L, Camuso J, Williams E, Kleinman K, Briones E, Schoenfeld D (1994) Effects of a small quantity of omega-3 fatty acids on cardiovascular risk factors in NIDDM. A randomized, prospective, double-blind, controlled study. Diabetes Care 17:37–44PubMedCrossRef

12.

Boberg M, Pollare T, Siegbahn A, Vessby B (1992) Supplementation with n-3 fatty acids reduces triglycerides but increases PAI-1 in non-insulin-dependent diabetes mellitus. Eur J Clin Investig 22:645–650CrossRef

13.

Brennan GM, McVeigh GE, Johnston GD, Hayes JR (1992) Dietary fish oil augments EDRF production or release in patients with non-insulin dependent diabetes mellitus. Br J Clin Pharmacol 33:531P (Abstract)

14.

Hendra TJ, Britton ME, Roper DR et al (1990) Effects of fish oil supplements in NIDDM subjects. Controlled study. Diabetes Care 13:821–829PubMedCrossRef

15.

Jain S, Gaiha M, Bhattacharjee J, Anuradha S (2002) Effects of low-dose omega-3 fatty acid substitution in type-2 diabetes mellitus with special reference to oxidative stress—a prospective preliminary study. J Assoc Phys India 50:1028–1033

16.

Maffettone A (1996) Long-term effects (six months) of omega-3 polyunsaturated fatty acids on insulin sensitivity and lipid metabolism in patients with type 2 diabetes and hypertriglyceridemia. G Ital Diabetol 16:185–193

17.

McGrath LT, Brennan GM, Donnelly JP, Johnston GD, Hayes JR, McVeigh GE (1996) Effect of dietary fish oil supplementation on peroxidation of serum lipids in patients with non-insulin dependent diabetes mellitus. Atherosclerosis 121:275–283PubMedCrossRef

18.

McVeigh GE, Brennan GM, Johnston GD et al (1993) Dietary fish oil augments nitric oxide production or release in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 36:33–38PubMedCrossRef

19.

McVeigh GE, Brennan GM, Cohn JN, Finkelstein SM, Hayes RJ, Johnston GD (1994) Fish oil improves arterial compliance in non-insulin-dependent diabetes mellitus. Arterioscler Thromb 14:1425–1429PubMed

20.

Meshcheriakova VA, Plotnikova OA, Sharafetdinov KH, Alekseeva RI, Mal’tsev GI, Kulakova SN (2001) Comparative study of effects of diet therapy including eiconol or linseed oil on several parameters of lipid metabolism in patients with type 2 diabetes mellitus. Vopr Pitan 70:28–31PubMed

21.

Mori TA, Woodman RJ, Burke V, Puddey IB, Croft KD, Beilin LJ (2003) Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic Biol Med 35:772–781PubMedCrossRef

22.

Patti L, Maffettone A, Iovine C et al (1999) Long-term effects of fish oil on lipoprotein subfractions and low density lipoprotein size in non-insulin-dependent diabetic patients with hypertriglyceridemia. Atherosclerosis 146:361–367PubMedCrossRef

23.

Rivellese AA, Maffettone A, Iovine C et al (1996) Long-term effects of fish oil on insulin resistance and plasma lipoproteins in NIDDM patients with hypertriglyceridemia. Diabetes Care 19:1207–1213PubMedCrossRef

24.

Silvis N, Vorster HH, Mollentze WF, Jager JD, Huisman HW (1988) Metabolic and haemostatic consequences of dietary fibre and n-3 fatty acids in black type 2 (NIDDM) diabetic subjects: a placebo controlled study. Int Clin Nutr Rev 10:362–380

25.

Sirtori CR, Paoletti R, Mancini M et al (1997) n-3 Fatty acids do not lead to an increased diabetic risk in patients with hyperlipidemia and abnormal glucose tolerance. Italian Fish Oil Multicenter Study. Am J Clin Nutr 65:1874–1881PubMed

26.

Vessby B, Boberg M (1990) Dietary supplementation with n-3 fatty acids may impair glucose homeostasis in patients with non-insulin-dependent diabetes mellitus. J Intern Med 228:165–171PubMedCrossRef

27.

Westerveld HT, de Graaf JC, van Breugel HH et al (1993) Effects of low-dose EPA-E on glycemic control, lipid profile, lipoprotein (a), platelet aggregation, viscosity, and platelet and vessel wall interaction in NIDDM. Diabetes Care 16:683–688PubMedCrossRef

28.

Woodman RJ, Mori TA, Burke V, Puddey IB, Watts GF, Beilin LJ (2002) Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr 76:1007–1015PubMed

29.

Woodman RJ, Mori TA, Burke V et al (2003) Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients. Atherosclerosis 166:85–93PubMedCrossRef

30.

Pedersen H, Petersen M, Major-Pedersen A et al (2003) Influence of fish oil supplementation on in vivo and in vitro oxidation resistance of low-density lipoprotein in type 2 diabetes. Eur J Clin Nutr 57:713–720PubMedCrossRef

31.

Pelikanova T, Kohout M, Valek J et al (1992) The effect of fish oil on the secretion and effect of insulin in patients with type II diabetes). Cas Lek Ces 131:668–672 (Czech)

32.

Pelikanova T, Kohout M, Valek J, Kazdova L, Base J (1993) Metabolic effects of omega-3 fatty acids in type 2 (non-insulin-dependent) diabetic patients. Ann N Y Acad Sci 683:272–278PubMedCrossRef

33.

Petersen M, Pedersen H, Major-Pedersen A, Jensen T, Marckmann P (2002) Effect of fish oil versus corn oil supplementation on LDL and HDL subclasses in type 2 diabetic patients. Diabetes Care 25:1704–1708PubMedCrossRef

34.

Morgan WA, Raskin P, Rosenstock J (1995) A comparison of fish oil or corn oil supplements in hyperlipidemic subjects with NIDDM. Diabetes Care 18:83–86PubMedCrossRef

35.

Goh YK, Jumpsen JA, Ryan EA, Clandinin MT (1997) Effect of omega 3 fatty acid on plasma lipids, cholesterol and lipoprotein fatty acid content in NIDDM patients. Diabetologia 40:45–52PubMedCrossRef

36.

Borkman M, Chisholm DJ, Furler SM et al (1989) Effects of fish oil supplementation on glucose and lipid metabolism in NIDDM. Diabetes 38:1314–1319PubMedCrossRef

37.

Connor WE, Prince MJ, Ullmann D et al (1993) The hypotriglyceridemic effect of fish oil in adult-onset diabetes without adverse glucose control. Ann N Y Acad Sci 683:337–340PubMedCrossRef

38.

Luo J, Rizkalla SW, Vidal H et al (1998) Moderate intake of n-3 fatty acids for 2 months has no detrimental effect on glucose metabolism and could ameliorate the lipid profile in type 2 diabetic men. Results of a controlled study. Diabetes Care 21:717–724PubMedCrossRef

39.

McManus RM, Jumpson J, Finegood DT, Clandinin MT, Ryan EA (1996) A comparison of the effects of n-3 fatty acids from linseed oil and fish oil in well-controlled type II diabetes. Diabetes Care 19:463–467PubMedCrossRef

40.

Schectman G, Kaul S, Kissebah AH (1988) Effect of fish oil concentrate on lipoprotein composition in NIDDM. Diabetes 37:1567–1573PubMedCrossRef

41.

Balk E, Chung M, Lichtenstein A et al (2004) Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease. Evidence report/technology assessment no. 93. Prepared by Tufts–New England Medical Center Evidence-based Practice Center. Agency for Healthcare Research and Quality, Rockville, MD

42.

Farmer A, Montori V, Dinneen S, Clar C (2001) Fish oil in people with type 2 diabetes mellitus. Cochrane Database Syst Rev CD003205

43.

Friedberg CE, Janssen MJ, Heine RJ, Grobbee DE (1998) Fish oil and glycemic control in diabetes. A meta-analysis. Diabetes Care 21:494–500PubMedCrossRef

44.

Montori VM, Farmer A, Wollan PC, Dinneen SF (2000) Fish oil supplementation in type 2 diabetes: a quantitative systematic review. Diabetes Care 23:1407–1415PubMedCrossRef

45.

Morris MC, Sacks F, Rosner B (1993) Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation 88:523–533PubMed

46.

Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ (2002) Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens 20:1493–1499PubMedCrossRef

47.

Cook NR, Cohen J, Hebert PR, Taylor JO, Hennekens CH (1995) Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 155:701–709PubMedCrossRef

48.

Blood Pressure Lowering Treatment Trialists’ Collaboration (2005) Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized Trials. Arch Intern Med 165:1410–1419CrossRef

49.

UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 317:703–713

50.

Dallongeville J, Yarnell J, Ducimetiere P et al (2003) Fish consumption is associated with lower heart rates. Circulation 108:820–825PubMedCrossRef

51.

Bao DQ, Mori TA, Burke V, Puddey IB, Beilin LJ (1998) Effects of dietary fish and weight reduction on ambulatory blood pressure in overweight hypertensives. J Hypertens 32:710–717

52.

Jouven X, Desnos M, Guerot C, Ducimetiere P (1999) Predicting sudden death in the population: The Paris Prospective Study I. Circulation 99:1978–1983PubMed

53.

Mozaffarian D, Geelen A, Brouwer IA, Geleijnse JM, Zock PL, Katan MB (2005) Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials. Circulation 112:1945–1952PubMedCrossRef

54.

Jouven X, Zureik M, Desnos M, Guerot C, Ducimetiere P (2001) Resting heart rate as a predictive risk factor for sudden death in middle-aged men. Cardiovasc Res 50:373–378PubMedCrossRef

55.

Balkau B, Jouven X, Ducimetiere P, Eschwege E (1999) Diabetes as a risk factor for sudden death. Lancet 354:1968–1969PubMedCrossRef

56.

Finnegan YE, Howarth D, Minihane AM et al (2003) Plant and marine derived (n-3) polyunsaturated fatty acids do not affect blood coagulation and fibrinolytic factors in moderately hyperlipidemic humans. J Nutr 133:2210–2213PubMed

57.

Norris PG, Jones CJ, Weston MJ (1986) Effect of dietary supplementation with fish oil on systolic blood pressure in mild essential hypertension. BMJ (Clin Res Ed) 293:104–105CrossRef

58.

Marckmann P, Bladbjerg EM, Jespersen J (1997) Dietary fish oil (4 g daily) and cardiovascular risk markers in healthy men. Arterioscler Thromb Vasc Biol 17:3384–3391PubMed

59.

Vanschoonbeek K, Feijge MAH, Paquay M et al (2004) Variable hypocoagulant effect of fish oil intake in humans: modulation of fibrinogen level and thrombin generation. Arterioscler Thromb Vasc Biol 24:1734–1740PubMedCrossRef

60.

Haines AP, Sanders TA, Imeson JD et al (1986) Effects of a fish oil supplement on platelet function, haemostatic variables and albuminuria in insulin-dependent diabetics. Thromb Res 43:643–655PubMedCrossRef

61.

Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW, The European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group (1995) Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 332:635–641PubMedCrossRef

62.

Wattanakit K, Folsom AR, Selvin E et al (2005) Risk factors for peripheral arterial disease incidence in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 180:389–397PubMedCrossRef

63.

Sanders TAB, Oakley FR, Miller GJ, Mitropoulos KA, Crook D, Oliver MF (1997) Influence of n-6 versus n-3 polyunsaturated fatty acids in diets low in saturated fatty acids on plasma lipoproteins and hemostatic factors. Arterioscler Thromb Vasc Biol 17:3449–3460PubMed

64.

Agren JJ, Vaisanen S, Hanninen O, Muller AD, Hornstra G (1997) Hemostatic factors and platelet aggregation after a fish-enriched diet or fish oil or docosahexaenoic acid supplementation. Prostaglandins Leukot Essent Fatty Acids 57:419–421PubMedCrossRef

65.

Kapur R, Hoffman CJ, Bhushan V, Hultin MB (1996) Postprandial elevation of activated factor VII in young adults. Arterioscler Thromb Vasc Biol 16:1327–1332PubMed

66.

Andersen P (1992) Hypercoagulability and reduced fibrinolysis in hyperlipidemia: relationship to the metabolic cardiovascular syndrome. J Cardiovasc Pharmacol 20(Suppl 8):S29–S31PubMed

67.

Hawe E, Talmud PJ, Miller GJ, Humphries SE (2003) Family history is a coronary heart disease risk factor in the Second Northwick Park Heart Study. Ann Hum Genet 67:97–106PubMedCrossRef

68.

Meade TW, Mellows S, Brozovic M et al (1986) Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 2:533–537PubMedCrossRef

69.

Junker R, Heinrich J, Schulte H, van de Loo J, Assmann G (1997) Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler Thromb Vasc Biol 17:1539–1544PubMed

70.

Salomaa V, Rasi V, Kulathinal S et al (2002) Hemostatic factors as predictors of coronary events and total mortality: The FINRISK ’92 Hemostasis Study. Arterioscler Thromb Vasc Biol 22:353–358PubMedCrossRef

71.

The GISSI Prevenzione Trial (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI–Prevenzione trial. Lancet 354:447–455CrossRef

72.

The AFORRD Trial (Atorvastatin in Factorial with Omega-3 risk Reduction in Diabetes) (2004) Register for randomised controlled trials, http://www.controlled-trials.com/isrctn/trial/|/0-76737502.html

73.

The ORIGIN Trial (Outcome Reduction with Initial Glargine Intervention) (2005) ClinicalTrials.gov Identifier: NCT00069784,http://www.controlledrials.com/mrct/trial/OMEGA%2D3%7CDIABETES/1059/61673.html

74.

The ASCEND Trial (2005) Oxford Clinical Trials Service Unit, http://www.ctsu.ox.ac.uk/ascend/

75.

Galan P, de Bree A, Mennen L et al (2003) Background and rationale of the SU.FOL.OM3 study: double-blind randomized placebo-controlled secondary prevention trial to test the impact of supplementation with folate, vitamin B6 and B12 and/or omega-3 fatty acids on the prevention of recurrent ischemic events in subjects with atherosclerosis in the coronary or cerebral arteries. J Nutr Health Aging 7:428–435PubMed

Titel: Meta-analysis of the effects of n-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes
verfasst von: J. Hartweg
A. J. Farmer
R. R. Holman
H. A. W. Neil
Publikationsdatum: 01.02.2007
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 2/2007
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-006-0486-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Eingreifen von Umstehenden rettet vor Erstickungstod!

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Aim/hypothesis

Methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2007

Angiotensin II receptor antagonist reduces urinary liver-type fatty acid-binding protein levels in patients with diabetic nephropathy and chronic renal failure

Progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a high-risk screening programme in general practice: the ADDITION Study, Denmark

Pregnancy plasma glucose levels exceeding the American Diabetes Association thresholds, but below the National Diabetes Data Group thresholds for gestational diabetes mellitus, are related to the risk of neonatal macrosomia, hypoglycaemia and hyperbilirubinaemia

Brain-derived neurotrophic factor (BDNF) and type 2 diabetes

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study